ARTAL GROUP S A
Q4 2022 Form 13-F
LUXEMBOURG
CIK 0001053906
· Institutional investment manager
Consolidated report · includes
5 managers
since Q2 2013
$1.8B Reported Value Total
Reported value
$1.8B
Quarter over quarter
-11.1%
Holdings
125
Top-10 concentration
44.3%
Reports holdings for
- Artal International S C A · File #028-15033 · since Q2 2013
- Westend S A · File #028-15029 · since Q2 2013
- Stichting Administratiekantoor Westend · File #028-15028 · since Q2 2013
- Artal International Management S A · File #028-15031 · since Q2 2013
- Artal Participations S.a r.l. (not a 13F filer in our records) · File #028-25146 · since Q4 2024
- Invus Public Equities Advisors LLC · File #028-11522 · Q2 2013 – Q2 2024
- Artal Luxembourg S A · File #028-19506 · Q1 2019 – Q1 2023
- Artal Treasury Ltd (not a 13F filer in our records) · File #028-19088 · Q4 2018 – Q4 2021
- Invus Advisors, L.L.C. (not a 13F filer in our records) · File #028-14596 · Q2 2013 – Q3 2013
Key People
Named on the latest Form 13-F filing — not necessarily an owner
Anne Goffard
Authorized Person
Filing Navigation
Coverage begins with the second quarter of 2013. Earlier quarters are not shown while their accuracy is being verified.
13F Metrics
Loading 13F Metrics
Q4 2022 13F record
Q4 2022 13F filing summary
| Period of report | December 31, 2022 |
|---|---|
| Filed | February 13, 2023 |
| Form | 13F-HR |
| Reported value | $1.8B |
| Positions | 125 |
| Change in reported value | -23.5% |
| New positions | 11 |
| Exited positions | 16 |
| Position turnover | 19.2% |
| Top-10 concentration | 44.3% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q2 2026 13F
Filed Aug 13, 2026
|
2 | $931.1M |
|
Q1 2026 13F
Filed May 14, 2026
|
2 | $1.0B |
|
Q4 2025 13F
Filed Feb 12, 2026
|
2 | $714.6M |
|
Q3 2025 13F
Filed Nov 12, 2025
|
2 | $758.2M |
|
Q2 2025 13F
Filed Aug 13, 2025
|
2 | $930.2M |
|
Q1 2025 13F
Filed May 14, 2025
|
2 | $884.2M |
|
Q4 2024 13F
Filed Feb 14, 2025
|
2 | $1.2B |
|
Q3 2024 13F
Filed Nov 13, 2024
|
2 | $2.4B |
|
Q2 2024 13F
Filed Aug 14, 2024
|
109 | $3.9B |
|
Q1 2024 13F
Filed May 13, 2024
|
107 | $3.9B |
|
Q4 2023 13F
Filed Feb 9, 2024
|
91 | $3.0B |
|
Q3 2023 13F
Filed Nov 13, 2023
|
101 | $2.3B |
|
Q2 2023 13F
Filed Aug 11, 2023
|
114 | $3.2B |
|
Q1 2023 13F
Filed May 12, 2023
|
118 | $1.7B |
|
Q4 2022 13F
Filed Feb 13, 2023
|
125 | $1.8B |
|
Q3 2022 13F
Filed Nov 14, 2022
|
130 | $2.3B |
|
Q2 2022 13F
Filed Aug 11, 2022
|
132 | $1.9B |
|
Q1 2022 13F
Filed May 12, 2022
|
135 | $2.4B |
|
Q4 2021 13F
Filed Feb 11, 2022
|
144 | $3.7B |
|
Q3 2021 13F
Filed Nov 12, 2021
|
140 | $4.5B |
33 earlier quarters on file — choose one from the quarter menu above.
Top 20 holdings · Q4 2022
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | LXRX LEXICON PHARMACEUTICALS INC | $171.5M | 9.57% |
| 2 | ONC BEIGENE LTD | $132.0M | 7.37% |
| 3 | MRTX MIRATI THERAPEUTICS INC | $83.0M | 4.64% |
| 4 | SRRK SCHOLAR ROCK HLDG CORP | $81.3M | 4.54% |
| 5 | CERE CEREVEL THERAPEUTICS HLDNG I | $59.9M | 3.34% |
| 6 | MORF MORPHIC HLDG INC | $57.5M | 3.21% |
| 7 | WGHTQ WW INTL INC | $57.2M | 3.19% |
| 8 | SWTX SPRINGWORKS THERAPEUTICS INC | $52.0M | 2.9% |
| 9 | KYMR KYMERA THERAPEUTICS INC | $49.9M | 2.79% |
| 10 | FOLD AMICUS THERAPEUTICS INC | $48.8M | 2.73% |
| 11 | APLS APELLIS PHARMACEUTICALS INC | $46.5M | 2.6% |
| 12 | CYTK CYTOKINETICS INC | $45.8M | 2.56% |
| 13 | IGMS IGM BIOSCIENCES INC | $41.7M | 2.33% |
| 14 | AGEN AGENUS INC | $34.8M | 1.94% |
| 15 | KRYS KRYSTAL BIOTECH INC | $31.7M | 1.77% |
| 16 | BLU BELLUS HEALTH INC NEW | $30.4M | 1.7% |
| 17 | KRTX KARUNA THERAPEUTICS INC | $29.5M | 1.65% |
| 18 | ALVR ALLOVIR INC | $28.6M | 1.6% |
| 19 | SAGE SAGE THERAPEUTICS INC | $28.6M | 1.6% |
| 20 | VIGL VIGIL NEUROSCIENCE INC | $28.0M | 1.57% |
Values as reported on the Q4 2022 Form 13F. Every position is in the holdings table below.